Association of Timing of Disease-Modifying Drug Treatment Initiation on Multiple Sclerosis Relapse Rates in Newly Diagnosed Patients

被引：0
|
作者：
Phillips, Amy [1 ]
Fang, Juanzhi [1 ]
Corvino, Frank [2 ]
Oliveri, David [2 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Genesis Res LLC, Hoboken, NJ USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P3.118
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity
    Bsteh, Gabriel
    Aicher, Marie L.
    Walde, Janette F.
    Krajnc, Nik
    Haider, Lukas
    Traxler, Gerhard
    Gradl, Christiane
    Salmen, Anke
    Riedl, Katharina
    Poskaite, Paulina
    Leyendecker, Philipp
    Altmann, Patrick
    Auer, Michael
    Berek, Klaus
    Di Pauli, Franziska
    Kornek, Barbara
    Leutmezer, Fritz
    Rommer, Paulus S.
    Zulehner, Gudrun
    Zrzavy, Tobias
    Deisenhammer, Florian
    Chan, Andrew
    Berger, Thomas
    Hoepner, Robert
    Hammer, Helly
    Hegen, Harald
    [J]. NEUROLOGY, 2024, 103 (06)
  • [22] Audit of patients switching disease-modifying therapies for the treatment of multiple sclerosis
    Embrey, NH
    Woolmore, JA
    Hawkins, CP
    [J]. MULTIPLE SCLEROSIS, 2005, 11 : S159 - S159
  • [23] Disease modifying therapies in people newly diagnosed with multiple sclerosis
    Von Geldern, G.
    Wundes, A.
    Mehta, D.
    Bet-Shlimon, S.
    Alschuler, K.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 529 - 529
  • [24] Time to relapse is comparable in pediatric-and adult-onset multiple sclerosis patients after the initiation of disease-modifying therapy
    Decard, B. F.
    von Wyl, V.
    Benkert, P.
    Lorscheider, J.
    Hanni, P.
    Lienert, C.
    Kuhle, J.
    Derfuss, T.
    Kappos, L.
    Yaldizli, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 545 - 546
  • [25] Review: In relapsing-remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates
    Weinshenker, Brian G.
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 160 (06)
  • [26] Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-modifying Drugs: A Systematic Review
    Hellwig, Kerstin
    Di Cantogno, Elisabetta Verdun
    Sabido, Meritxell
    [J]. NEUROLOGY, 2021, 96 (15)
  • [27] Disease-modifying treatment of secondary progressive multiple sclerosis
    Hoffmann, Olaf
    Gold, Ralf
    [J]. NERVENARZT, 2021, 92 (10): : 1052 - 1060
  • [28] Real-World Assessment of Relapse Rates in Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon β-1a vs Oral Disease-Modifying Drugs
    Kozma, Chris
    Munschauer, Frederick
    Phillips, Amy
    [J]. NEUROLOGY, 2016, 86
  • [29] Cost-Sharing and Initiation of Disease-Modifying Therapy for Multiple Sclerosis
    Romley, John
    Goldman, Dana
    Eber, Michael
    Dastani, Home
    Kim, Edward
    Raparla, Swetha
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2012, 18 (08): : 460 - 464
  • [30] Disease-modifying treatments for patients with multiple sclerosis in Spain
    Perez, Alejandro Santiago
    Casado, Santos Esteban
    Payero, Miriam Alvarez
    Pueyo, Angel Escolano Escolano
    Bernabe, Angel Guillermo Arevalo
    Zamora, Nuria Padulles
    Ruiz, Pilar Diaz
    Gonzalez, Ana Maria Lopez
    [J]. FARMACIA HOSPITALARIA, 2023, 47 (04) : 155 - 160
12345